Last updated: 31 May 2024 at 6:30pm EST

Cam Gallagher Net Worth




The estimated Net Worth of Cam Gallagher is at least $23.3 millió dollars as of 31 May 2024. Cam Gallagher owns over 9,597 units of Zentalis Pharmaceuticals, Llc stock worth over $2,059,460 and over the last 12 years Cam sold ZNTL stock worth over $21,220,669.

Cam Gallagher ZNTL stock SEC Form 4 insiders trading

Cam has made over 40 trades of the Zentalis Pharmaceuticals, Llc stock since 2020, according to the Form 4 filled with the SEC. Most recently Cam sold 9,597 units of ZNTL stock worth $114,972 on 31 May 2024.

The largest trade Cam's ever made was selling 36,739 units of Zentalis Pharmaceuticals, Llc stock on 4 December 2020 worth over $2,020,278. On average, Cam trades about 10,977 units every 27 days since 2012. As of 31 May 2024 Cam still owns at least 633,680 units of Zentalis Pharmaceuticals, Llc stock.

You can see the complete history of Cam Gallagher stock trades at the bottom of the page.



What's Cam Gallagher's mailing address?

Cam's mailing address filed with the SEC is C/O ZENTALIS PHARMACEUTICALS, INC., 1359 BROADWAY, SUITE 801, NEW YORK, NY, 10018.

Insiders trading at Zentalis Pharmaceuticals, Llc

Over the last 5 years, insiders at Zentalis Pharmaceuticals, Llc have traded over $106,453,887 worth of Zentalis Pharmaceuticals, Llc stock and bought 5,536,611 units worth $121,990,782 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management Company,... és Anthony Y Sun. On average, Zentalis Pharmaceuticals, Llc executives and independent directors trade stock every 11 days with the average trade being worth of $188,516. The most recent stock trade was executed by Cam Gallagher on 31 May 2024, trading 9,597 units of ZNTL stock currently worth $114,972.



What does Zentalis Pharmaceuticals, Llc do?

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.



What does Zentalis Pharmaceuticals, Llc's logo look like?

Zentalis Pharmaceuticals, Llc logo

Complete history of Cam Gallagher stock trades at Sorrento Therapeutics Inc és Zentalis Pharmaceuticals, Llc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
31 May 2024 Cam Gallagher
elnök és Interim CFO
Eladás 9,597 $11.98 $114,972
31 May 2024
633,680
12 Feb 2024 Cam Gallagher
elnök és Interim CFO
Eladás 1,173 $11.44 $13,419
12 Feb 2024
643,277
1 Feb 2024 Cam Gallagher
elnök és Interim CFO
Eladás 11,552 $11.54 $133,310
1 Feb 2024
644,450
31 May 2023 Cam Gallagher
elnök és Interim CFO
Eladás 27,768 $26.27 $729,465
31 May 2023
463,502
13 Feb 2023 Cam Gallagher
elnök és Interim CFO
Eladás 11,833 $20.09 $237,725
13 Feb 2023
491,270
6 Feb 2023 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $22.27 $222,700
6 Feb 2023
503,103
17 Jan 2023 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $24.15 $241,500
17 Jan 2023
352,011
5 Jan 2023 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $21.02 $210,200
5 Jan 2023
362,011
15 Nov 2022 Cam Gallagher
elnök és Interim CFO
Eladás 12,500 $22.77 $284,625
15 Nov 2022
372,011
7 Nov 2022 Cam Gallagher
elnök és Interim CFO
Eladás 24,874 $23.62 $587,524
7 Nov 2022
384,511
17 Oct 2022 Cam Gallagher
elnök és Interim CFO
Eladás 12,500 $23.51 $293,875
17 Oct 2022
409,385
5 Oct 2022 Cam Gallagher
elnök és Interim CFO
Eladás 22,500 $22.45 $505,125
5 Oct 2022
421,885
15 Sep 2022 Cam Gallagher
elnök és Interim CFO
Eladás 22,500 $24.90 $560,250
15 Sep 2022
444,385
5 Apr 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $50.48 $504,800
5 Apr 2022
355,813
15 Mar 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $41.92 $419,200
15 Mar 2022
365,813
7 Mar 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $44.94 $449,400
7 Mar 2022
375,813
15 Feb 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $51.93 $519,300
15 Feb 2022
385,813
10 Feb 2022 Cam Gallagher
elnök és Interim CFO
Eladás 7,188 $50.19 $360,766
10 Feb 2022
395,813
7 Feb 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $53.45 $534,500
7 Feb 2022
387,203
18 Jan 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $62.64 $626,400
18 Jan 2022
397,203
5 Jan 2022 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $75.49 $754,900
5 Jan 2022
407,203
15 Dec 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $74.03 $740,300
15 Dec 2021
417,203
6 Dec 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $71.33 $713,300
6 Dec 2021
427,203
15 Nov 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $75.36 $753,600
15 Nov 2021
437,203
5 Nov 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $82.95 $829,500
5 Nov 2021
447,203
1 Oct 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $66.15 $661,500
1 Oct 2021
457,203
1 Sep 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $67.52 $675,200
1 Sep 2021
467,203
2 Aug 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $51.02 $510,200
2 Aug 2021
477,203
6 Jul 2021 Cam Gallagher
elnök és Interim CFO
Eladás 18,370 $46.92 $861,920
6 Jul 2021
487,203
2 Jul 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $49.58 $495,800
2 Jul 2021
505,573
1 Jun 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $54.06 $540,600
1 Jun 2021
515,573
3 May 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $59.25 $592,500
3 May 2021
525,573
5 Apr 2021 Cam Gallagher
elnök és Interim CFO
Eladás 28,369 $43.40 $1,231,215
5 Apr 2021
535,573
1 Mar 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $41.69 $416,900
1 Mar 2021
563,942
1 Feb 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $37.49 $374,900
1 Feb 2021
560,192
4 Jan 2021 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $51.93 $519,300
4 Jan 2021
570,192
24 Dec 2020 Cam Gallagher
elnök és Interim CFO
Eladás 18,473 $57.20 $1,056,656
24 Dec 2020
0
4 Dec 2020 Cam Gallagher
elnök és Interim CFO
Eladás 36,739 $54.99 $2,020,278
4 Dec 2020
580,192
2 Dec 2020 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $51.43 $514,300
2 Dec 2020
616,931
23 Nov 2020 Cam Gallagher
elnök és Interim CFO
Eladás 10,000 $46.54 $465,400
23 Nov 2020
626,931


Zentalis Pharmaceuticals, Llc executives and stock owners

Zentalis Pharmaceuticals, Llc executives and other stock owners filed with the SEC include: